



Advance in Nanoparticles as Vaccine Adjuvants

Guest Editors:

Dr. Eduardo Gomez-Casado

Department of Biotechnology,
INIA-CSIC, 28040 Madrid, Spain

Dr. Sohrab Ahmadivand

Faculty of Veterinary Medicine,
Ludwig Maximilian University of
Munich, 80539 München,
Germany

Deadline for manuscript
submissions:

30 June 2024

Message from the Guest Editors

Dear Colleagues,

Remarkable efforts have been made to develop new and improved vaccines attending antigen's nature and immune mechanisms involved. To obtain an appropriate humoral and cell-mediated immunity, risk-free and effective vaccines are needed against infectious diseases and tumoral processes. In the last years, nanoparticles have gained much interest in new vaccines generation since they can protect the antigen targets from premature proteolytic degradation, lead to a homogeneous uptake of antigens by immune cells, and facilitating their processing and presentation. Nanoparticles composed of lipids, proteins, metals or polymers have already been used to attain some of these attributes. This special issue aims to collect recent original research and reviews on nanoparticulate-loaded vaccines attain their nature, formulation, delivery, their safe and efficacy, and induced immune responses to accomplish efficient and long-lasting protection against infectious diseases and tumors. I look forward to receiving your contributions.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPLus / SciFinder**, and **other databases**.

Journal Rank: JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

Contact Us

Vaccines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com